Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Fish and Richardson
Covington
QuintilesIMS
Farmers Insurance
Argus Health
AstraZeneca
Fuji
Citi

Generated: October 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,079,262

« Back to Dashboard

Claims for Patent: 5,079,262

Title: Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
Abstract:A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin, conjunctives, respiratory, digestive and vaginal mucosa; endometrium and urothelium in which 5-aminolevulinic acid is administered to the patient in an amount sufficient to induce synthesis of protoporphyrin IX in the leisons, followed by exposure of the treated lesion to a photoactivating light in the range 350-640 nm.
Inventor(s): Kennedy; James C. (Kingston, CA), Pottier; Roy H. (Kingston, CA), Reid; Robert L. (Kingston, CA)
Assignee: Queen's University at Kingston (Kingston, CA)
Application Number:07/386,414
Patent Claims: 1. A method for treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium; and urothelium which are sensitive to protoporphyrin IX in a patient in need thereof comprising administering to said patient an effective amount of 5-aminolevulinic acid so as to induce synthesis of protoporphyrin IX in said lesions, and exposing said lesions to light within the photoactivating action spectrum of said photoporphyrin IX.

2. A method as claimed in claim 1 wherein said malignant lesions are selected from basal, baso-squamous and squamous carcinomas.

3. A method as claimed in claim 1 wherein said non-malignant lesions are selected from psoriasis and genital warts.

4. A method as claimed in claim 1 wherein said photoactivating light is in the range 350-640 nm.

5. A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered parenterally.

6. A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered topically.

7. A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered orally.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
Daiichi Sankyo
Queensland Health
Deloitte
Harvard Business School
Mallinckrodt
US Army
Chubb
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot